Obesity Management and Redux by Stylianos Nicolaidis

By Stylianos Nicolaidis

Redux™ is a innovative new anti-obesity drug that has simply been licensed (July 1996) through the FDA. it's the first weight administration drug therapy to be introduced within the usa in two decades and isn't addictive, not like prior medicines used for this goal. weight problems administration and Redux™ encompasses a short advent which leads as much as its discovery and contains an summary of latest developments in weight problems administration. The e-book lists the pharmacological profile of the drug, given by means of specialists all for tracking the results of the drug at the mind neurotransmitters, in addition to detailing the implications (including defense info) of some of the scientific trials. Key positive aspects* Covers all elements of a progressive new drug* Lists pharmacological profile of the drug* contains safeguard information* tasks destiny developments in weight administration

Show description

Read Online or Download Obesity Management and Redux PDF

Similar endocrinology & metabolism books

Principles of Molecular Regulation

Oregon health and wellbeing Sciences Univ. , Portland. built-in overview of membrane receptor-initiated telephone signalling and nuclear receptor-initiated gene rules. provides an in-depth remedy of cyclic AMP, protein kinases, and protein phosphatases. For medical and base researchers.

Principles of Gender-Specific Medicine, Second Edition

The sphere of gender-specific drugs examines how general human biology and body structure differs among women and men and the way the analysis and therapy of illness differs as a functionality of gender. This revealing study covers a variety of stipulations that predominantly happen in males besides stipulations that predominantly take place in ladies.

Obesity: Prevention and Treatment

The superiority of weight problems within the usa and the remainder of the industrialized global has skyrocketed some time past two decades. associated with middle ailment, diabetes, high blood pressure, and metabolic syndrome, it's also the best reason for osteoarthritis and the second one best reason for melanoma. With contributions from major specialists within the box.

Treatment of the Obese Patient

This can be a well timed and informative up to date version for all healthiness care companies challenged with supporting sufferers deal with weight. just like the well-reviewed first variation, this up to date name is directed towards people who desire to learn additional approximately unique subject matters, instead of locate an advent to the sphere.

Extra resources for Obesity Management and Redux

Example text

Weinsier RC, Johnston MH, Doleys DM, Bacon JA (1982) Dietary management of obesity: Evaluation of the time-energy displacement diet in terms of its efficacy and nutritional adequacy for long-term weight control. B r J Nutr 47: 367-379. Welch I, Saunders K, Read NW (1985) Effect of ileal and intravenous infusions of fat emulsions on feeding and satiety in human volunteers. Gastroenterology 89: 12931297. Wurtman JJ, Wurtman RJ, Growdon JH (1982) Carbohydrate craving in obese people: suppression by treatments affecting serotoninergic transmission.

1987) Goodall and Silverstone (1988) Blundell and Hill (1988) Hill and Blundell (1986) a Subjects' weight Dosing Assessment Change in energy intake Normal 1 day Normal 1 day Single test meal Single test (2 h) 40% test meal intake 25% test meal intake Normal 1 day Normal 5 days Single test meal Single test meal; diary records 11% test meal intake 18% test meal intake Normal 5 days Hill and Obese Blundell (1990) a Wurtman et al. Obese (CHO (1985) cravers) Wurtman et al. (1987) Andersen et al. (1989) 3 days 8 days Obese (CHO cravers) 3 months Obese (nonCHO cravers) 3 months Obese 6 months Single test meal Measured meals and snacks Measured meals and snacks Measured meals and snacks Diary records 25% total daily intake $11% test meal intake $ 23% total daily intake 22% total daily intake 22% total daily intake $ 13% total daily intake more than placebo a15 mg on test day; all other studies 30 mg; CHO, carbohydrates.

1978). These drugs accumulate in the brain, and give rise to metabolites (see Fig. , 1989, 1991). This short review focuses on the activity on food intake shown by agents that affect 5-HT transmission. There is no evidence that blocking the metabolism of 5-HT by monoamine oxidase inhibitors reduces food intake. Inhibition of 5-HT uptake is another way of increasing extracellular 5-HT concentrations. , 1993), presumably by inhibiting 5-HT uptake by nerve terminals. , 1993). However, a dissociation between 5-HT uptake inhibition Obesity Management and ReduxVM ISBN 0-12-518170-1 Copyright ~) 1997 Academic Press Ltd All rights of reproduction in any form reserved R E CH2CH3 d-FENFLURAMINE R=H d-NORFENFLURAMINE Fig.

Download PDF sample

Rated 4.54 of 5 – based on 40 votes